Showing 131-140 of 1916 results for "".
"You've Just Been Served": Dr. Goldberg
https://practicaldermatology.com/programs/practical-dermatology/youve-just-been-served-dr-goldberg/32691/David Goldberg, MD, JD, discusses lessening the likelihood of lawsuits and winning lawsuits involving negligence, employees, and teledermatology, which he covered during his session, "You've Just Been Served," at Maui Derm 2025.Join Us for NewDerm LIVE: Welcome from the Chairs
https://practicaldermatology.com/topics/practice-management/join-us-for-newderm-live-welcome-from-the-chairs/18920/Join us September 18-20, 2015 at the W Hollywood, CA for NewDerm Live, the meeting that's focused on you—so you can focus on your future. Program chairs Sabrina Fabi, MD, Peter Lio, MD, and Kavita Mariwalla, MD, talk about the goals of the meeting and explain why they decided to be part of this exciNail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.Dr. Joel Schlessinger discusses Botox treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-joel-schlessinger-discusses-botox-treatments/19321/Joel Schlessinger, MD takes you through a BOTOX treatment step-by-step, explaining each piece of the process. The video begins with a quick description of BOTOX, Dysport and Xeomin before moving on to show the process of taking pre-treatment photos and performing a consultation. Dr. Schlessinger theDermWireTV 09.12.19: Otezla to Amgen, A Juvéderm First, Skin Cancer Foundation News
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-091219-otezla-to-amgen-a-juvederm-first-skin-cancer-foundation-news/19663/After traveling more than 10,000 miles across the US, the Skin Cancer Foundation’s “Destination: Healthy Skin” Program is wrapping up for the season. Plus, the Champions for Change Gala is coming October 17. Amgen has entered into an agreement with Celgene Corporation Company to acquire worldwide riDermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More
https://practicaldermatology.com/topics/practice-management/dermwiretv-inclusion-in-derm-amgen-incyte-janssen-dermavant-updates-klisyri-launch-more/19901/For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using theirTechnology Solutions: Q&A With Nextech's Dr. Jason Handza
https://practicaldermatology.com/topics/practice-management/technology-solutions-q-nextechs-dr-jason-handza/28649/Nextech this year introduced Nextech RCM Professional Billing Services, an addition to their practice management software suite. This solution simplifies insurance billing complexities, helping practices reduce administrative burdens and enhance financial performance through optimized cash flow.Updates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.